Clinical Trials Logo

ESR1 Gene Mutation clinical trials

View clinical trials related to ESR1 Gene Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05814224 Recruiting - Breast Neoplasms Clinical Trials

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

MAGNETIC1
Start date: May 22, 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.

NCT ID: NCT04174352 Recruiting - ESR1 Gene Mutation Clinical Trials

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

Start date: October 20, 2020
Phase: Early Phase 1
Study type: Interventional

Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and transcriptional regulation that is always "turned on" despite the absence of estrogen. Patients with ESR1 mutations are expected to have decreased binding affinity for tamoxifen and thus may be underdosed on standard therapy. [18F]-fluoroestradiol Positron Emission Tomography/Computed tomography (FES-PET/CT) imaging is a novel functional imaging technique that can non-invasively measure ERα expression and inhibition in metastatic ERα+ breast cancer. The proposed a pilot study uses FES-PET/CT imaging to measure ERα blockade to determine the optimal dose of tamoxifen in patients with ESR1 mutations.